New drug doesn't improve disability among stroke patients

February 3, 2012

A new drug that showed promise in animal studies and an early clinical trial didn't improve disability among stroke patients, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

After a stroke and other types of brain damage, the brain naturally produces more granulocyte colony stimulating factor (G-CSF). The protein can prevent further cell injury by protecting and boosting .

The new drug, AX200, is a manufactured form of G-CSF.

Ninety days after treatment, patients receiving AX200 or a placebo both scored a three on the 0-6 modified Rankin scale, a common test for stroke-related disability.

In a secondary analysis, also at day 90, researchers assessed patients with the National Institutes of Health Stroke Scale. The difference between the drug and placebo was less than half a point (8.88 on AX200 vs. 8.45 on placebo), which was statistically insignificant.

"These top line results are disappointing and unexpected to us because AX200 showed signs of efficacy in a previous clinical trial with a limited number of patients, as well as in numerous animal studies," said Bernd Ringelstein, M.D., lead author of the study and Professor of at the University of Münster, Germany.

"At this time, we cannot speculate about their implications, but our current conclusion is that we were not able to show efficacy for AX200 as a treatment for acute ischemic stroke. We will have to analyze the complete data set in order to fully understand these results."

The study was conducted between August 2009 and November 2011 on 328 patients at 78 stroke treatment centers in eight European countries. The average age of the patients was 69 years and 52 percent were male.

Continuous intravenous infusion of AX200 began within nine hours of first symptoms and lasted for three days. Neither patients nor researchers knew which participants randomly received the drug or .

In the United States, stroke is the No. 4 killer and a primary cause of long-term disability among adults. The most common type, ischemic stroke, is caused by a blocked blood vessel to the brain.

Stroke warning signs are:

  • Sudden numbness or weakness of the face, arm or leg, especially on one side of the body
  • Sudden confusion, trouble speaking or understanding
  • Sudden trouble seeing in one or both eyes
  • Sudden trouble walking, dizziness, loss of balance or coordination
  • Sudden severe headache with no known cause
If any of the symptoms occur, call 9-1-1 immediately, the American Stroke Association advises.

Explore further: Use of clot busters for stroke increased from 2005 to 2009, but still low

Related Stories

Use of clot busters for stroke increased from 2005 to 2009, but still low

June 2, 2011
The use of clot-busting drugs to treat acute ischemic stroke increased from 2005 through 2009 — but is still low, according to research reported in Stroke: Journal of the American Heart Association.

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.